153 related articles for article (PubMed ID: 36765744)
1. Nicotinaldehyde, a Novel Precursor of NAD Biosynthesis, Abrogates the Anti-Cancer Activity of an NAD-Lowering Agent in Leukemia.
Matsumoto S; Biniecka P; Bellotti A; Duchosal MA; Nahimana A
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765744
[TBL] [Abstract][Full Text] [Related]
2. Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia.
ElMokh O; Matsumoto S; Biniecka P; Bellotti A; Schaeuble K; Piacente F; Gallart-Ayala H; Ivanisevic J; Stamenkovic I; Nencioni A; Nahimana A; Duchosal MA
Cell Death Dis; 2022 Apr; 13(4):320. PubMed ID: 35396381
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel NAMPT inhibitor that selectively targets NAPRT-deficient EMT-subtype cancer cells and alleviates chemotherapy-induced peripheral neuropathy.
Kim M; Kim H; Kang BG; Lee J; Kim T; Lee H; Jung J; Oh MJ; Seo S; Ryu MJ; Sung Y; Lee Y; Yeom J; Han G; Cha SS; Jung H; Kim HS
Theranostics; 2023; 13(14):5075-5098. PubMed ID: 37771778
[No Abstract] [Full Text] [Related]
4. Reactive oxygen/nitrogen species contribute substantially to the antileukemia effect of APO866, a NAD lowering agent.
Cloux AJ; Aubry D; Heulot M; Widmann C; ElMokh O; Piacente F; Cea M; Nencioni A; Bellotti A; Bouzourène K; Pellegrin M; Mazzolai L; Duchosal MA; Nahimana A
Oncotarget; 2019 Nov; 10(62):6723-6738. PubMed ID: 31803365
[TBL] [Abstract][Full Text] [Related]
5. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies.
Nahimana A; Attinger A; Aubry D; Greaney P; Ireson C; Thougaard AV; Tjørnelund J; Dawson KM; Dupuis M; Duchosal MA
Blood; 2009 Apr; 113(14):3276-86. PubMed ID: 19196867
[TBL] [Abstract][Full Text] [Related]
6. Structure-Based Identification and Biological Characterization of New NAPRT Inhibitors.
Franco J; Piacente F; Walter M; Fratta S; Ghanem M; Benzi A; Caffa I; Kurkin AV; Altieri A; Herr P; Martínez-Bailén M; Robina I; Bruzzone S; Nencioni A; Del Rio A
Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890155
[TBL] [Abstract][Full Text] [Related]
7. NAD pool as an antitumor target against cancer stem cells in head and neck cancer.
Navas LE; Blanco-Alcaina E; Suarez-Martinez E; Verdugo-Sivianes EM; Espinosa-Sanchez A; Sanchez-Diaz L; Dominguez-Medina E; Fernandez-Rozadilla C; Carracedo A; Wu LE; Carnero A
J Exp Clin Cancer Res; 2023 Mar; 42(1):55. PubMed ID: 36864434
[TBL] [Abstract][Full Text] [Related]
8. APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells.
Cagnetta A; Caffa I; Acharya C; Soncini D; Acharya P; Adamia S; Pierri I; Bergamaschi M; Garuti A; Fraternali G; Mastracci L; Provenzani A; Zucal C; Damonte G; Salis A; Montecucco F; Patrone F; Ballestrero A; Bruzzone S; Gobbi M; Nencioni A; Cea M
Clin Cancer Res; 2015 Sep; 21(17):3934-45. PubMed ID: 25964294
[TBL] [Abstract][Full Text] [Related]
9. Nicotinamide Phosphoribosyltransferase Inhibitor APO866 Prevents IL-1β-Induced Human Nucleus Pulposus Cell Degeneration via Autophagy.
Shi C; Wu H; Du D; Im HJ; Zhang Y; Hu B; Chen H; Wang X; Liu Y; Cao P; Tian Y; Shen X; Gao R; van Wijnen AJ; Ye X; Yuan W
Cell Physiol Biochem; 2018; 49(6):2463-2482. PubMed ID: 30261504
[TBL] [Abstract][Full Text] [Related]
10. NAD⁺ depletion by APO866 in combination with radiation in a prostate cancer model, results from an in vitro and in vivo study.
Zerp SF; Vens C; Floot B; Verheij M; van Triest B
Radiother Oncol; 2014 Feb; 110(2):348-54. PubMed ID: 24412016
[TBL] [Abstract][Full Text] [Related]
11. Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery.
Ghanem MS; Caffa I; Del Rio A; Franco J; Parenti MD; Monacelli F; Cea M; Khalifa A; Nahimana A; Duchosal MA; Ravera S; Bertola N; Bruzzone S; Nencioni A; Piacente F
Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890147
[TBL] [Abstract][Full Text] [Related]
12. A critical role of autophagy in antileukemia/lymphoma effects of APO866, an inhibitor of NAD biosynthesis.
Ginet V; Puyal J; Rummel C; Aubry D; Breton C; Cloux AJ; Majjigapu SR; Sordat B; Vogel P; Bruzzone S; Nencioni A; Duchosal MA; Nahimana A
Autophagy; 2014 Apr; 10(4):603-17. PubMed ID: 24487122
[TBL] [Abstract][Full Text] [Related]
13. Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase.
Zhang LY; Liu LY; Qie LL; Ling KN; Xu LH; Wang F; Fang SH; Lu YB; Hu H; Wei EQ; Zhang WP
Eur J Pharmacol; 2012 Jan; 674(2-3):163-70. PubMed ID: 22119381
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of NAMPT sensitizes MOLT4 leukemia cells for etoposide treatment through the SIRT2-p53 pathway.
Grohmann T; Penke M; Petzold-Quinque S; Schuster S; Richter S; Kiess W; Garten A
Leuk Res; 2018 Jun; 69():39-46. PubMed ID: 29653431
[TBL] [Abstract][Full Text] [Related]
15. EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition.
Zucal C; D'Agostino VG; Casini A; Mantelli B; Thongon N; Soncini D; Caffa I; Cea M; Ballestrero A; Quattrone A; Indraccolo S; Nencioni A; Provenzani A
BMC Cancer; 2015 Nov; 15():855. PubMed ID: 26542945
[TBL] [Abstract][Full Text] [Related]
16. How Does
Anand G; Waiger D; Vital N; Maman J; Ma LJ; Covo S
Front Microbiol; 2019; 10():329. PubMed ID: 30873138
[TBL] [Abstract][Full Text] [Related]
17. Targeting the vulnerability to NAD
Takao S; Chien W; Madan V; Lin DC; Ding LW; Sun QY; Mayakonda A; Sudo M; Xu L; Chen Y; Jiang YY; Gery S; Lill M; Park E; Senapedis W; Baloglu E; Müschen M; Koeffler HP
Leukemia; 2018 Mar; 32(3):616-625. PubMed ID: 28904384
[TBL] [Abstract][Full Text] [Related]
18. Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.
Chini CC; Guerrico AM; Nin V; Camacho-Pereira J; Escande C; Barbosa MT; Chini EN
Clin Cancer Res; 2014 Jan; 20(1):120-30. PubMed ID: 24025713
[TBL] [Abstract][Full Text] [Related]
19. Properly Substituted Benzimidazoles as a New Promising Class of Nicotinate Phosphoribosyltransferase (NAPRT) Modulators.
Baldassarri C; Giorgioni G; Piergentili A; Quaglia W; Fontana S; Mammoli V; Minazzato G; Marangoni E; Gasparrini M; Sorci L; Raffaelli N; Cappellacci L; Petrelli R; Del Bello F
Pharmaceuticals (Basel); 2023 Jan; 16(2):. PubMed ID: 37259338
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.
Tan B; Young DA; Lu ZH; Wang T; Meier TI; Shepard RL; Roth K; Zhai Y; Huss K; Kuo MS; Gillig J; Parthasarathy S; Burkholder TP; Smith MC; Geeganage S; Zhao G
J Biol Chem; 2013 Feb; 288(5):3500-11. PubMed ID: 23239881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
